GVK BIO strengthens tie-up with CTC Life Science Japan

GVK announced its strategic tie with CTC Life Science Corporation (CTCLS) to market and distribute its proprietary ‘Drug Repurposing Platform’ in Japan.


(Photo Courtesy: www.enterprisevisions.com)

The drug repurposing platform called GRIP (GVK Bio Repurposing Integrated Platform) is a combination of several GVK Bio proprietary and several public domain databases.

It calls for reinvestigating the marketed drugs, clinical and/or pre-clinical candidates and can be applied to many different compounds including those that have failed to show efficacy in late stage clinical trials.

GVK offers a full blown drug repurposing collaborative research services starting from in-silico hypothesis generation to IND enabling studies under one roof.

In addition, GRIP is capable of addressing drug-based, target-based and disease-based repurposing requests and also for generic drugs and innovative compounds (drugs with patent validity, shelved, and pre-clinical stage).

Underlying the Drug Repositioning process is a set of 8 distinct algorithms that allow for unbiased interpretation of the input data to predict alternative indications.


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email